Gilead is now waiting for regulatory decisions on the twice-yearly PrEP in Europe and other markets, including South Africa ...

EY's latest Biotech Beyond Borders report acknowledges the seismic changes in the US in the last few months, including cuts ...

Skyclarys is an important growth product for Biogen, which has been hit in the last few years by a series of pipeline ...

Small transactions may not always make the headlines, but they’re the lifeblood of pharma innovation. So says Juergen ...

A smartphone app developed by Otsuka and digital health firm Click Therapeutics has been launched in Great Britain – its ...

The PMS requirement applies to all UKCA- and CE-marked devices, like in vitro diagnostics (IVDs), glucose monitors, and ...

The financing has been billed as the most significant commercial investment into Welsh research to date, and will help Draig ...

NHS cost-effectiveness overseer NICE has published new guidance recommending IL-36 inhibitor Spevigo (spesolimab) for the ...

The Commissioner's National Priority Voucher (CNPV) programme will be available to companies aligned with pressing matters ...

FDA Commissioner Marty Makary has revealed a new priority review voucher programme for new medicines deemed to be of national ...

Published in the Journal of the American Medical Association (JAMA), the letter says that the dismissal of the advisors and the appointment of eight new ACIP members two days later, along with ...

Eli Lilly has confirmed plans for a $1.3 billion takeover bid for Verve Therapeutics, upgrading a collaboration between the ...